Archive | MaxCyte

BioBuzz: For 20 Years This Company Has Helped to Shape the Field of Cell Therapy

Maxcyte logo square

How MaxCyte Has Evolved to Become Leading Technology Provider for Cell Engineering and Leveraged Its Flow Electroporation® Technology and Know-How to Launch Its Own Robust CAR Pipeline  MaxCyte, located in Gaithersburg, Maryland, is a unique biotech company that is a key anchor of the robust and growing Maryland cell and gene therapy industry. Founded in 1999, […]

Comments Off on BioBuzz: For 20 Years This Company Has Helped to Shape the Field of Cell Therapy Continue Reading →

Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines

MAXCYTE-New-Logo-2016-LARGE

CAMBRIDGE, Mass., and GAITHERSBURG, Md., – October 7, 2019:– Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine will use MaxCyte’s Flow Electroporation® technology and ExPERT™ instruments for the advancement of engineered cell […]

Comments Off on Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines Continue Reading →

MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform

MAXCYTE-New-Logo-2016-LARGE

–      No dose-limiting toxicities or safety concerns observed in first cohort of treated patients–      Feasibility of streamlined, faster CAR therapy manufacturing process confirmed–      Dosing initiated in second cohort of patients Gaithersburg, Maryland – May 8, 2019: MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that it […]

Comments Off on MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform Continue Reading →

MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing

MAXCYTE-New-Logo-2016-LARGE

– CARMA drug candidates can be manufactured via streamlined, single-day process, providing a much needed faster turnaround of autologous cell therapy to patients– CARMA cell therapies are engineered with the intention of reducing potential adverse events that have been evident with other CAR technologies and to allow for multiple dosing, an important feature for potential […]

Comments Off on MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing Continue Reading →